An Initial Survey on the Prevalence of Group B Streptococcus (GBS) among Yemeni Pregnant Women.

Ibrahim Hasan AL-Subol (alsabalibrahim@gmail.com)
University of Science and Technology https://orcid.org/0000-0002-0036-5646
Maha Abdul-Aziz
University of Science and Technology Sana'a Yemen
Abdullah A. Almikhlafy
University of Science and Technology Sana'a Yemen
Talal Y Alqahtani
Technology and Science Institute of Northern Taiwan: Taipei City University of Science and Technology

Research

Keywords: GBS, Streptococcus agalactiae, neonatal infections, Colonization, Gestation

Posted Date: December 21st, 2020

DOI: https://doi.org/10.21203/rs.3.rs-125786/v1

Abstract

Background: Neonatal infection with group B *Streptococcus* (GBS) is still a threat to the life of fetus and mother, especially in developing countries that do not adopt a prenatal screening test policy.

Objective: This study aimed to estimate the prevalence of group B *Streptococcus* in pregnant Yemeni women between the 35th and 39th weeks of gestation and also to assess group B *Streptococcus* sensitivity pattern to several antibiotics.

Methods: The fieldwork was performed in a primary health centre and a private modern medical laboratory at Sana'a city, Yemen. The study was limited to taking one vaginal swab from each participant of 210 pregnant women, and it relied on the cultural characteristics and biochemical tests for identifying the bacteria as group B *Streptococcus*. Antibiotic susceptibility testing was performed using the Kirby-Bauer test.

Results: Among the 210 pregnant women who were participating in this study, 23 (10.95%) were vaginally colonized with group B *Streptococcus*. Beta-lactam antibiotics and vancomycin were completely effective against group B *Streptococcus*.

Conclusion: Based on this study results, at least one out of every ten

Ymenei pregenant women is GBS vaginally colonized therefore we recommend routine prenatal GBS screening among pregnant women in the third trimester in Yemen and conducting extensive epidemiological studies in other Yemeni cities to detect the extent prevalence of GBS among pregnant mothers in Yemen in order to develop an appropriate preventive strategy.

Introduction

The year 2016 marks the implementation of the united nations sustainable development goals (SDGs) [1]. One of these seventeen goals is to enhance mother, neonate, and child health and plans to end mother and child deaths from preventable diseases [1]. To achieve these goals, neonatal fatalities in each nation should be about 12 per 1000 live births by 2030 [2, 3]. In general, infectious diseases are considered an important cause of maternal, neonatal, and childhood mortality in low and middle-income countries [4, 5]. Despite the falling in maternal mortality with substantial variation among countries and within countries globally [6, 7], it is still high especially in low industrial base and Human Development Index (HDI) countries. In 2017, about 295 thousand women died during pregnancy or after giving birth. Ninety-four percent of these deaths occurred in countries of low and lower middle income countries, and most of them could have been prevented [8]. Maternal infection is a significant and possible etiology of worldwide maternal death. Worldwide, between 2003 and 2009, It was estimated that maternal infections caused around 10.7% (5.9–18.6%) (261 000) of mother deaths [9]. Maternal health and neonatal health are closely related. Between 2000 and 2015, 9 of the 10 causes of infant death most rapidly reduced were infectious diseases [4]. Among preterm birth and neonatal encephalopathy, it is found that infectious

diseases play a role as an important primary contributor to them, whereas both preterm and neonatal encephalopathy are leading causes of neonatal mortality and subsequent adverse outcomes worldwide [10, 11, 12]. In 2013, 3.257 million (51.7%) of the 6.3 million under-five children's deaths were due to infectious diseases, and 2.761 million (44%) died during delivery [4]. The current global strategy has become the trend towards detecting dangerous bacteria causing possible infection either to prevent or to treat the newborn with a suitable antibiotic.

Group B *Streptococcus (Streptococcus agalactiae)* bacteria colonize the female reproductive and gastrointestinal tracts without symptoms. Around 20 to 30% of healthy women carry group B *Streptococcus*, and can transmit the organism to their neonate. The consequences of maternal and fetal infections with group B *Streptococcus* range from asymptomatic colonization to septicemia that cause life-threatening newborn diseases, such as meningitis, pneumonia, and septic shock [13]. Worldwide, there is a considerable variation in the prevalence of GBS vaginal colonization, ranging from high (35%) in the Caribbean to a much lower prevalence (13%) and (11%) in Southern Asia and Eastern Asia, respectively [14]. Variation of prevalence was also reported in different Arab countries. In Jordan, the maternal vaginal colonization by Group B Streptococcus was 19.5% [15], while the rates were lower in Saudi Arabia, Egypt, and the United Arab Emirates, 15.0%, 11.3%, and 10.1% respectively [16–18]. As we stated before, GBS infection can lead to maternal death, stillbirth, and neonatal death [19–22]. Besides, neurological impairment may result among survival neonates and infants after GBS infection [23]. GBS has been implicated in adverse pregnancy outcomes, including preterm labour and an increase in neonatal encephalopathy [24, 25]. Yemen is one of the developing world countries and its population is vulnerable to many diseases, including bacterial diseases. Up to date, there is no data about the prevalence of GBS among pregnant Yemeni women in spite that GBS is an important perinatal pathogen. Therefore, this study aimed to estimate group B *Streptococcus* prevalence among pregnant Yemeni women in Sana'a city, Yemen.

Methodology

Study design, population, and place

We conducted this cross-sectional study over four months (from June to September, 2019) to determine the prevalence of group B streptococcus vaginal colonization among two hundred and ten pregnant women between the 35th and 39th weeks of gestation attending Gaza medical center in Sana'a city, Yemen. All microbiological procedures (culture, identifying bacteria, and antibiotic susceptibility testing) were carried out in the I Lab (a private modern medical laboratory).

Sample size

The sample was calculated using OpenEpi.com (an open-source web tool) based on an expected prevalence of 15% (according to other regional previous studies) at a confidence level of 95% and an accepted marginal error of 5%. Thus, the calculated sample was 196 participant and our study involved

210 pregnant women in anticipation of excluding any participant that did not meet the criteria of participation.

Specimen and data collection

After the participant consent, a sterile single vaginal swab containing Amies transport medium was used to collect a swab sample from each participant within the specified pregnant period. Vaginal sampling was carried out by a trained nurse by rotating a swab against the vaginal introitus wall, CDC guidelines [26]. The swabs were properly labeled with specimen numbers and transferred immediately to the I Lab for micobiological proceduers. Data about age, education level, parity, the number of previous miscarriages, and other question regarding possible risk factors of (GBS) colonization were collected via face-to-face interviews using a structured questionnaire form.

Specimen culture and bacterial identification

The obtained vaginal swab samples were inoculated into culture tubes containing Todd-Hewitt broth with gentamicin (8 µg/mL) and nalidixic acid (15 µg/mL). Inoculated tubes were incubated at 37 °C for 24 h, then subcultured on 5% human blood agar plates and incubated at 37 °C for 24 h. The isolated colonies on human blood agar plates were identified as *S. agalactiae* by the following criteria: colony morphology, Gram stain, hemolysis, catalase, and CAMP test [27]. The results were interpreted by an expert microbiologist at the University of Science and Technology.

Antibiotic susceptibility testing

Antibiotic susceptibility testing for penicillin, ampicillin, levofloxacin, cefotaxime, clindamycin, vancomycin, and tetracycline was performed for all *S. agalactiae* isolates using the Kirby-Bauer test (the disk diffusion method) on Mueller-Hinton agar with 5% human blood according to CLSI guidelines [28].

Research ethics

The approval to conduct this study was obtained from the University of Science and Technology medical research ethics committee, NO (ECA/UST191)..

Data analysis

The results were tabulated and analyzed by IBM SPSS Statistics version 23 for Windows® (IBM Corp., Armonk, NY, USA). Descriptive statistics included frequencies and cross-tabulation; however, the significance of difference was tested by Chi-square and Fisher exact tests. The significance level (P-value) of less than 0.05 was considered significant.

Results

Participant characteristics

The study period extended from June to September 2019 and included 210 pregnant women with a mean age (26.14 ± 5.28 years) ranging from 16 to 38 years who attended to Gaza medical center, at Sana'a, Yemen between the 35th and 39th weeks of gestation.

Colonization rate

The results of this study showed that 23 pregnant women (10.95%) with 95% CI (6.95–14.95%) were positive for vaginal colonization by group B *Streptococcus* based on cultures in Todd-Hewitt broth and on 5% human blood agar plates and other identification tests mentioned in methodology. The mean age of pregnant women with positive GBS vaginal colonization was (26.47 ± 6.5 years), whereas it was (26.1 ± 5.12 years) for the rest of the participants. The mean gestational age of pregnant women with positive GBS vaginal colonization was (37.17 ± 1.34 weeks), whereas it was (36.91 ± 1.08 weeks) for the rest of the participants, and this means that there is no correlation between the factors (patients'age and gestational age) and the GBS vaginal colonization.

Risk factors

The results of the statistical analysis of the risk factor variables (parity, previous abortions, and educational level) showed that there were no statistical significance differences (P-value 0.05) between the two groups of participants (positive and negative group B *Streptococcus* vaginal colonization) as shown in (Table 1).

Table 1
Association between GBS vaginal colonization and Parity, Previous Abortions, and Educational level.

	Colonization				
	Yes		No		P-value
	N	%	N	%	
Parity					0.517
0	2	18.20%	9	81.80%	
1	5	12.50%	35	87.50%	
2	3	5.80%	49	94.20%	
3 or more	13	12.10%	94	87.90%	
Previous Abortions					0.82
No	17	11.30%	134	88.70%	
	6	10.20%	53	89.80%	
Educational level					0.565
Basic	7	8.60%	74	91.40%	
Illiterate	8	14.80%	46	85.20%	
Secondary	8	11.60%	61	88.40%	
University	0	0.00%	6	100.00%	

Antibiotic susceptibility testing

An antibiotic susceptibility test was performed for all 23 identified GBS isolates. All isolates were sensitive to penicillin, ampicillin, levofloxacin, cefotaxime, and vancomycin, while the sensitivity of bacteria to clindamycin and tetracycline decreased to be 82.8% and 30.5% respectively, (Table 2).

Table 2
Antibiotic susceptibility testing results of GBS isolates

Antibiotic		N	%
Penicillin	I	0	0.00%
	R	0	0.00%
	S	23	100.00%
Ampicillin	I	0	0.00%
	R	0	0.00%
	S	23	100.00%
Levofloxacin	I	0	0.00%
	R	0	0.00%
	S	23	100.00%
Cefotaxime	I	0	0.00%
	R	0	0.00%
	S	23	100.00%
Clindamycin	I	2	8.60%
	R	2	8.60%
	S	19	82.80%
Vancomycin	I	0	0.00%
	R	0	0.00%
	S	23	100.00%
Tetracycline	I	5	21.70%
	R	11	47.80%
	S	7	30.50%
I = intermediate, R = resistant, and S = sensitive			

Discussion

Although pregnant women must be screened for GBS as part of routine prenatal care, no problem estimation and no official Yemeni guidelines regarding GBS in pregnant women have been established. This cross-sectional study was conducted on 210 Yemeni pregnant women to investigate the prevalence

rate of vaginal colonization by GBS for the first time in Yemen. The present study revealed that 10.95% of Yemeni pregnant women were vaginally colonized with GBS. This result is consistent with the findings of several similar studies from developing countries where the GBS vaginal colonization ranged from 10–15%. For instance, it was 11.8% in Iran [29], 10.4% in Ethiopia [30], 14% in Cameroon [31], and 15% in Bangladish [32]. However, GBS vaginal colonization in other countries was reported to be less than that of our. For example, it was 8.2% in China [33], 7.6% in Saudi Arabia [34]. and 2%in India [35]. Additionally, higher colonization rates were reported in other countries. It was 26% in Brazil [36], 19.5% in Jordan [15], and 30.9% in South Africa [37]. The variation of colonization rates among different studies is attributed to several factors, such as the site of swaping (vaginal, rectal or both), different numbers of participants, different personal hygiene behaviours, different sexual practices behaviours, antibiotic use, and different ways to isolate bacteria. In this study the prevalence was less than other studies owing to that we did not obtain approval from participants to take rectal swabs. Other possible factors are religion and culture belives, personal hygiene, sexual practices, and antibiotic use. By analyzing the relationship of different variables (parity, previous abortions, and educational level) with vaginal group B *Streptococcus* colonization, we did not find significant relationship between these variables and vaginal colonization (Table 1). This finding conforms to the findings of other research, such as [15, 29, 38, 39]. In the twentieth century the excessive use of antibiotics has heightened fear of raised concerns regarding the emergence of bacterial antibiotic resistance [40]. Therefore, earlier studies have also been performed to find out the sensitivity of group B *Streptococcus* and its resistance to various antibiotics [41–43]. According to the results of this study, the antibiotic sensitivity profile of GBS was as follows; all isolates were sensitive to penicillin, ampicillin, levofloxacin, cefotaxime, and vancomycin. These findings are close to those of other studies, such as [44] done in Nigeria, [45] in Saudi Arabia, and [30] in Ethiopia. Generally, Penicillin as yet the drug of choice for prophylaxis and treatment of GBS colonization in pregnant women. Thus, our results is consistent with different studies regarding the sensitivity to penicillin [30, 43, 45, 46]. Our study findings do not correspond to the Ethiopian research results where the highest resistance was observed against penicillin [47]. Women who were penicillin-allergic clindamycin is recommended for GBS prophylaxis during labor [42]. Group B *Streptococcus* resistance rate to different antibiotics have been detected to be increased in many regions of the world, including Europe [48], North America [49], and South America [50]. In the last 10 years, GBS strains had exhibited resistance to other antibiotics, including erythromycin and clindamycin [51]. Clindamycin and/or erythromycin resistance has already been notified earlier, ranging from 0.7–51.3% for erythromycin and from 1.7 to 50% for clindamycin. [52, 53]. Resistance rate of GBS to clindamycin in the current study was 8.6% and this rate is close to clindamycin resistant rate (5.1%) in Saudi Arabia [45]. The different antibiotic sensitivity rates of group B *Streptococcus* among different studies are due to many factors, such as antibiotics misuse, self-treatment with antibiotics, different isolated strains. The high sensitivity rates of GBS to members of beta-lactam family as well as its increased resistance to other antibiotics supports the pivotal role of penicillin and ampicillin as the first-line for intrapartum treatment to prevent neonatal early-onset infection by GBS.

Conclusion And Recommendation

We conclude that 11% of pregnant Yemeni women carrying group B *Streptococcus* (GBS) bacteria in their vaginal environment. Also, all group B *Streptococcus* isolates were sensitive to beta-lactam antibiotics, and thus penicillin remains the first choice for treatment and prophylaxis at the prenatal period in women who carry these bacteria and do not show allergy to penicillin. We recommend routine prenatal GBS screening among pregnant women in the third trimester in Yemen. We also recommend conducting extensive epidemiological studies that include other cities to detect the extent prevalence of GBS among pregnant mothers in Yemen in order to develop an appropriate preventive strategy.

Declarations

Ethics approval and consent to participate

approved from research ethics committee of the University of Science and Technology in Sana'a city, NO: ECA/UST191

Consent for publication

Not applicable

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request

Competing interests

we declare that we have no competing interests

Funding

no funding

Authors' contributions

All authors read and approved the final manuscript

Acknowledgements

We would like to thank the participants. We equally thank Gaza center staff for providing assistance with specimen collection.

References

1. *United Nations Sustainable Development – 17 Goals to Transform Our World*. www.un.org/sustainabledevelopment/.
2. Lawn, Joy E, et al. Every Newborn: Progress, Priorities, and Potential beyond Survival. The Lancet. 2014;384(9938):189–205. doi:10.1016/s0140-6736(14)60496-7.
3. Chou D, et al. Ending Preventable Maternal and Newborn Mortality and Stillbirths. Bmj. 2015. doi:10.1136/bmj.h4255.
4. Liu, Li, et al. Global, Regional, and National Causes of Child Mortality in 2000–13, with Projections to Inform Post-2015 Priorities: an Updated Systematic Analysis. The Lancet. 2015;385(9966):430–40. doi:10.1016/s0140-6736(14)61698-6.
5. Murray, Christopher JL, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. The lancet. 2012;380(9859):2197–223.
6. Alkema L, et al. Global, Regional, and National Levels and Trends in Maternal Mortality Between 1990 and 2015, With Scenario-Based Projections to 2030. Obstetric Anesthesia Digest. 2016;36(4):191. doi:10.1097/01.aoa.0000504718.91214.7d.
7. “Maternal Mortality.” *World Health Organization*, World Health Organization, .
8. “Trends in Maternal Mortality 2000 to 2017: Estimates by WHO, UNICEF, UNFPA, World Bank Group and the United Nations Population Division. Executive Summary.” *World Health Organization*, World Health Organization, 1 Jan. 1970, apps.who.int/iris/handle/10665/327596.
9. Say L, et al. “Global Causes of Maternal Death: a WHO Systematic Analysis.” The Lancet Global Health, 2, 6, 2014, doi:10.1016/s2214-109x(14)70227-x.
10. Seale AC, et al. Neonatal Severe Bacterial Infection Impairment Estimates in South Asia, Sub-Saharan Africa, and Latin America for 2010. Pediatr Res. 2013;74, no. S1:73–85. doi:10.1038/pr.2013.207.
11. Blencowe H, et al. “Preterm Birth–Associated Neurodevelopmental Impairment Estimates at Regional and Global Levels for 2010.” *Pediatric Research*, vol. 74, no. S1, 2013, pp. 17–34., doi:10.1038/pr.2013.204.
12. Lee A, Cc, et al. Intrapartum-Related Neonatal Encephalopathy Incidence and Impairment at Regional and Global Levels for 2010 with Trends from 1990. Pediatr Res. 2013;74, no. S1:50–72. doi:10.1038/pr.2013.206.
13. Cunningham F, Gary. *Williams Obstetrics*. McGraw-Hill Eduction, 2018.
14. Russell, Neal J, et al. “Maternal Colonization With Group B Streptococcus and Serotype Distribution Worldwide: Systematic Review and Meta-Analyses.” Clin Infect Dis, 65, suppl_2, 2017,

doi:10.1093/cid/cix658.

15. Clouse K, et al. High Prevalence of Group B Streptococcus Colonization among Pregnant Women in Amman, Jordan. Am J Obstet Gynecol. 2017;217(6):739. doi:10.1016/j.ajog.2017.08.035.
16. Mohamed A. Mohamed, et al. “Group B Streptococcus Colonization, Antibiotic Susceptibility, and Serotype Distribution among Saudi Pregnant Women. Infection Chemotherapy. 2020;52(1):70. doi:10.3947/ic.2020.52.1.70.
17. Wassef M, et al. Rapid Screening for Group BStreptococcusin near-Term Pregnant Women by Granada™ Biphasic Broth. The Journal of Maternal-Fetal Neonatal Medicine. 2016;30(13):1540–3. doi:10.1080/14767058.2016.1199679.
18. Amin A, et al. Group B Streptococcal Serotype Distribution of Isolates from Colonized Pregnant Women at the Time of Delivery in United Arab Emirates. J Infect. 2002;45(1):42–6. doi:10.1053/jinf.2001.0990.
19. Hall J, et al. “Maternal Disease With Group B Streptococcus and Serotype Distribution Worldwide: Systematic Review and Meta-Analyses.” Clin Infect Dis, 65, suppl_2, 2017, doi:10.1093/cid/cix660.
20. Seale, Anna C, et al. “Stillbirth With Group B Streptococcus Disease Worldwide: Systematic Review and Meta-Analyses.” Clin Infect Dis, 65, suppl_2, 2017, doi:10.1093/cid/cix585.
21. Madrid L, et al. “Infant Group B Streptococcal Disease Incidence and Serotypes Worldwide: Systematic Review and Meta-Analyses.” Clin Infect Dis, 65, suppl_2, 2017, doi:10.1093/cid/cix656.
22. Seale, Anna C, et al. “Estimates of the Burden of Group B Streptococcal Disease Worldwide for Pregnant Women, Stillbirths, and Children.” Clin Infect Dis, 65, suppl_2, 2017, doi:10.1093/cid/cix664.
23. K-L. Maya, et al. “Neurodevelopmental Impairment in Children After Group B Streptococcal Disease Worldwide: Systematic Review and Meta-Analyses.” Clin Infect Dis, 65, suppl_2, 2017, doi:10.1093/cid/cix663.
24. B-J. Fiorella, et al. “Preterm Birth Associated With Group B Streptococcus Maternal Colonization Worldwide: Systematic Review and Meta-Analyses.” Clin Infect Dis, 65, suppl_2, 2017, doi:10.1093/cid/cix661.
25. Tann, Cally J, et al “Neonatal Encephalopathy With Group B Streptococcal Disease Worldwide: Systematic Review, Investigator Group Datasets, and Meta-analysis.” *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America* vol. 65,suppl_2 (2017): S173-S189. doi:10.1093/cid/cix662. DOI: 10.1093/cid/cix662.
26. *Prevention of Perinatal Group B Streptococcal Disease: Revised Guidelines from CDC, 2010*. *Morbidity and Mortality Weekly Report*, *59*, 1–32.
27. Cheesbrough M. *District Laboratory Practice in Tropical Countries*. Cambridge University Press, 2006.
28. Clinical and Laboratory Standards Institute. (2015). Performance standards for antimicrobial susceptibility testing; 25th Informational Supplement. CLSI Document M100-S25, Clinical and Laboratory Standards Institute, Wayne, PA.

29. Darabi R, et al. The Prevalence and Risk Factors of Group B Streptococcus Colonization in Iranian Pregnant Women. Electronic Physician. 2017;9(5):4399–404. doi:10.19082/4399.
30. Mengist A, et al. “Prevalence and Antimicrobial Susceptibility Pattern of Anorectal and Vaginal Group B Streptococci Isolates among Pregnant Women in Jimma, Ethiopia.” BMC Research Notes, 9, 1, 2016, doi:10.1186/s13104-016-2158-4.
31. Nkembe N. Marius, et al. “Streptococcus Agalactiae Prevalence and Antimicrobial Susceptibility Pattern in Vaginal and Anorectal Swabs of Pregnant Women at a Tertiary Hospital in Cameroon.” BMC Research Notes, 11, 1, 2018, doi:10.1186/s13104-018-3589-x.
32. Saha SK, et al. Group B Streptococcus among Pregnant Women and Newborns in Mirzapur, Bangladesh: Colonization, Vertical Transmission, and Serotype Distribution. J Clin Microbiol. 2017;55(8):2406–12. doi:10.1128/jcm.00380-17.
33. Ji W, et al. “Colonization Prevalence and Antibiotic Susceptibility of Group B Streptococcus in Pregnant Women over a 6-Year Period in Dongguan, China.” Plos One, 12, 8, 2017, doi:10.1371/journal.pone.0183083.
34. Hussain T. “Epidemiology of Group B Streptococcus in Saudi Parturient Women in a Private Hospital.” Obstetrics Gynecology: An International Journal, 2015, 1–7., doi:10.5171/2015.376062.
35. Khatoon F, et al. “Prevalence and Risk Factors for Group B Streptococcal Colonization in Pregnant Women in Northern India.” International Journal of Reproduction Contraception Obstetrics Gynecology, 2016, 4361–4., doi:10.18203/2320-1770.ijrcog20164343.
36. Wollheim C, et al. Group B Streptococcus Detection in Pregnant Women via Culture and PCR Methods. Revista Da Sociedade Brasileira De Medicina Tropical. 2017;50(2):179–83. doi:10.1590/0037-8682-0454-2016.
37. Monyama M, et al. Group B Streptococcus Colonisation in Pregnant Women at Dr. George Mukhari Hospital, South Africa. Southern African Journal of Infectious Diseases. 2016;31(3):74–8. doi:10.1080/23120053.2016.1156308.
38. De Melo -SCristinaCSabaini, et al. “Prevalence of Streptococcus Agalactiae Colonization in Pregnant Women from the 18th Health Region of Paraná State.” Revista Do Instituto De Medicina Tropical De São Paulo, 60, 2018, doi:10.1590/s1678-9946201860002.
39. Assefa S, et al. “Group B Streptococci Vaginal Colonization and Drug Susceptibility Pattern among Pregnant Women Attending in Selected Public Antenatal Care Centers in Addis Ababa, Ethiopia.” BMC Pregnancy Childbirth, 18, 1, 2018, doi:10.1186/s12884-018-1791-4.
40. Azavedo JCS, De, et al. Prevalence and Mechanisms of Macrolide Resistance in Invasive and Noninvasive Group B Streptococcus Isolates from Ontario, Canada. Antimicrob Agents Chemother. 2001;45(12):3504–8. doi:10.1128/aac.45.12.3504-3508.2001.
41. Andrews JI, et al. Group B Streptococci Causing Neonatal Bloodstream Infection: Antimicrobial Susceptibility and Serotyping Results from SENTRY Centers in the Western Hemisphere. Am J Obstet Gynecol. 2000;183(4):859–62. doi:10.1067/mob.2000.108839.

42. *Prevention of Perinatal Group B Streptococcal Disease: Revised Guidelines from CDC, 2010*. MMWR Recomm Rep. 19;59(RR-10):1–36.
43. Atalay A, et al. Antibiotic Susceptibilities and Serotyping Of Clinical Streptococcus Agalactiae Isolates. Medical Journal of Trakya University. 2010. doi:10.5174/tutfd.2010.03979.2.
44. Ezeonu IM, Agbo MC. Incidence and Anti-Microbial Resistance Profile of Group B Streptococcus (GBS) Infection in Pregnant Women in Nsukka, Enugu State, Nigeria. African Journal of Microbiology Research. 2014;8(1):91–5. doi:10.5897/ajmr12.2307.
45. Khan M. Ahmad, et al. “Maternal Colonization of Group B Streptococcus: Prevalence, Associated Factors and Antimicrobial Resistance. Ann Saudi Med. 2015;35(6):423–7. doi:10.5144/0256-4947.2015.423.
46. Wang P, et al. “Serotypes, Antibiotic Susceptibilities, and Multi-Locus Sequence Type Profiles of Streptococcus Agalactiae Isolates Circulating in Beijing, China.” Plos One, 10, 3, 2015, doi:10.1371/journal.pone.0120035.
47. Mengist H, Mihiretie, et al. “Prevalence and Drug Susceptibility Pattern of Group B Streptococci (GBS) among Pregnant Women Attending Antenatal Care (ANC) in Nekemte Referral Hospital (NRH), Nekemte, Ethiopia.” BMC Research Notes, 10, 1, 2017, doi:10.1186/s13104-017-2725-3.
48. Gherardi G, et al. Molecular Epidemiology and Distribution of Serotypes, Surface Proteins, and Antibiotic Resistance among Group B Streptococci in Italy. J Clin Microbiol. 2007;45(9):2909–16. doi:10.1128/jcm.00999-07.
49. Phares, Christina R. “Epidemiology of Invasive Group B Streptococcal Disease in the United States, 1999–2005.” *Jama*, vol. 299, no. 17, 2008, p. 2056., doi:10.1001/jama.299.17.2056.
50. Pinto TC, Abreu, et al. Distribution of Serotypes and Evaluation of Antimicrobial Susceptibility among Human and Bovine Streptococcus Agalactiae Strains Isolated in Brazil between 1980 and 2006. The Brazilian Journal of Infectious Diseases. 2013;17(2):131–6. doi:10.1016/j.bjid.2012.09.006.
51. Nakamura P, Am, et al. Antimicrobial Resistance Profiles and Genetic Characterisation of Macrolide Resistant Isolates of Streptococcus Agalactiae. Memórias Do Instituto Oswaldo Cruz. 2011;106(2):119–22. doi:10.1590/s0074-02762011000200001.
52. Ferjani A, et al. Vaginal colonization of the Streptococcus agalactiae in pregnant woman in Tunisia: risk factors and susceptibility of isolates to antibiotics. *Bulletin de la Societe de pathologie exotique (*1990*)* vol. 99,2 (2006): 99–102.
53. Boswihi SS, et al. Serotypes and Antibiotic Resistance in Group B Streptococcus Isolated from Patients at the Maternity Hospital, Kuwait. J Med Microbiol. 2012;61(1):126–31. doi:10.1099/jmm.0.035477-0.